PTGX Q1 2022 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+315.6% YoY

Gross Profit

$25M96.8% margin

Operating Income

-$21M-82.1% margin

Net Income

-$21M-81.4% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+198.5%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$348M

Total Liabilities

$47M

Stockholders' Equity

$302M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$6M	+315.6%
Gross Profit	$25M	$6M	+302.1%
Operating Income	-$21M	-$24M	+12.1%
Net Income	-$21M	-$24M	+12.8%

Revenue Segments

License and Collaboration Agreement

$26M100%